STEM -- StemCells, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc.

STEM 16.67

+1.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (26)	2/25/1997 4:23:00 PM
From: James Silverman	of 805

You've touched upon the same issues that have confused me in regards to NXCO. I believe that NXCO has the exclusive rights to the conopeptides for the pain indication. I cannot verify this. Its also important to note that "apparently" NXCO tried to get Dr. Oliv. to join them-he declined. IMO this collaboration is a big deal for CTII. Cognetix is also working with SIBI-in terms of running the various compounds through SIBI assays targetted for Parkinson's and other CNS conditions. I am unclear on how CTII/Cogn will affect their work. Calls to the various companies (NXCO/SIBI/CTII/Cognetix) would be in order to clear through this maze.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next